In lieu of hard M&A news, one group of an­a­lysts crunch­es the num­bers around a $40B Seagen buy

Some of the an­a­lysts at SVB Se­cu­ri­ties have been play­ing with the num­bers that might set the stage for Mer­ck $MRK — or some oth­er Big Phar­ma — to come in and make a buy­out of Seagen $SGEN work. And while it’s all pure spec­u­la­tion, it does help pro­vide a rough out­line for what a deal could look like in H2 as in­vestors wait with bat­ed breath for the bot­tom of a mis­er­able pub­lic biotech mar­ket.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE